Business Context and Reporting Period
Company: DNA X, Inc. (formerly Sonim Technologies, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Reporting Status: Non-accelerated filer; Smaller reporting company.
Business Overview: The Company has pivoted from manufacturing rugged cell phones and hotspots to operating a cryptocurrency trading platform (DNA X). On January 23, 2026, the Company completed the sale of substantially all assets of its legacy phone and hotspot business to Pace Car Acquisition LLC for approximately $15.0 million. The legacy business is reported as discontinued operations. The Company now focuses exclusively on the DNA X platform, which allows users to trade cryptocurrencies and automate trading strategies.
Key Financial Metrics
| Metric | 2025 (Continuing Ops) | 2025 (Discontinued Ops) | 2024 (Total) |
|---|---|---|---|
| Net Revenues | $0 | $56,894 | $58,298 |
| Net Loss | $(7,955) | $(12,702) | $(33,648) |
| Cash and Cash Equivalents | $1,303 (as of Dec 31, 2025) | ||
| Total Debt (Promissory Notes) | $5,065 (net carrying value) | ||
| Stockholders' Deficit | $(7,955) |
Note: All figures in thousands except per share data. Continuing operations revenue is negligible ($27 in commissions) as the platform launched in November 2025.
Material Changes vs. Prior Period
- Strategic Pivot: The Company ceased its legacy hardware manufacturing business, which is now classified as discontinued operations. The 2025 results reflect a transition period with minimal revenue from the new crypto platform.
- Net Loss Reduction: Total net loss decreased from $(33.6) million in 2024 to $(20.7) million in 2025, primarily due to the cessation of the loss-making hardware business and a tax benefit of $1.1 million recognized in discontinued operations.
- Debt Structure: The Company incurred significant new debt in 2025, including a $1.2 million convertible note from DNA Holdings and promissory notes from Streeterville Capital (paid off in Jan 2026). Interest expense for continuing operations was $1.5 million in 2025 compared to $29k in 2024.
- Capital Structure: A 1-for-18 reverse stock split was effected in October 2025. The Company raised capital through public offerings and ATM sales, netting approximately $13.7 million in equity proceeds in 2025.
Guidance, Outlook, Risks, and Contingencies
Going Concern Uncertainty
The independent auditor has issued a report containing a statement of substantial doubt regarding the Company's ability to continue as a going concern. The Company expects the $3.5 million cash proceeds from the asset sale (closed Jan 2026) to fund operations only through the second quarter of 2026. Additional equity or debt financing is required to sustain operations.
Outlook and Strategy
Management plans to grow the DNA X platform by adding new cryptocurrencies, implementing staking features, and increasing marketing spend in 2026. Revenue is currently driven by trading commissions (approx. 0.4% of volume). Trading volume was $6,721 in December 2025, generating $27 in revenue.
Key Risks and Contingencies
- Put Option Risk: The Company issued 223,201 redeemable shares to DNA Holdings for the platform acquisition. DNA Holdings holds a put option exercisable until June 30, 2026, if the platform fails to achieve $600 million in aggregate trading volume or $1 million in daily revenue. If exercised, the Company could lose ownership of the platform.
- Regulatory Uncertainty: Significant risks exist regarding the classification of cryptocurrencies as securities by the SEC and other regulators, which could impact the platform's ability to operate or list certain assets.
- Internal Controls: Management identified a material weakness in internal control over financial reporting due to a lack of personnel with sufficient technical accounting expertise for complex transactions (e.g., the DNA X acquisition).
- Nasdaq Compliance: The Company previously failed to meet the $2.5 million stockholders' equity requirement but regained compliance following the asset sale in January 2026.
Investor Verification Checklist
- Going Concern Status: Verify the Company's ability to secure additional funding before Q2 2026 to avoid insolvency.
- Put Option Milestones: Monitor trading volume and daily revenue metrics against the $600M/$1M thresholds required to prevent DNA Holdings from reclaiming the platform.
- Revenue Trajectory: Assess the growth of trading volume and commission revenue from the DNA X platform, which was negligible at year-end 2025.
- Debt Obligations: Review the terms of the remaining $1.2 million convertible note to DNA Holdings and any new financing terms.
- Internal Controls: Confirm remediation of the material weakness in financial reporting identified in the 2025 audit.